Suvaxyn Circo+MH RTU
Porcine circovirus and porcine enzootic pneumonia vaccine (inactivated)
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Suvaxyn Circo+MH RTU.It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Suvaxyn Circo+MH RTU.
For practical information about using Suvaxyn Circo+MH RTU, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Authorisation details
Product details | |
---|---|
Name |
Suvaxyn Circo+MH RTU
|
Agency product number |
EMEA/V/C/003924
|
Active substance |
|
International non-proprietary name (INN) or common name |
Porcine circovirus and porcine enzootic pneumonia vaccine (inactivated)
|
Species |
Pigs
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI09AL
|
Publication details | |
---|---|
Marketing-authorisation holder |
Zoetis Belgium SA
|
Revision |
7
|
Date of issue of marketing authorisation valid throughout the European Union |
06/11/2015
|
Contact address |
Rue Laid Burniat 1 |
Product information
14/10/2021 Suvaxyn Circo+MH RTU - EMEA/V/C/003924 - IB-0018
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Therapeutic indication
For active immunisation of pigs from 3 weeks of age against porcine circovirus type 2 (PCV2) to reduce viral load in blood and lymphoid tissues and fecal shedding caused by infection with PCV2.
For active immunisation of pigs over the age of 3 weeks against Mycoplasma hyopneumoniae to reduce lung lesions caused by infection with M. hyopneumoniae.